Actualités sur Health

05.09.2008 – 11:00
European Society for Medical Oncology (ESMO)
33rd ESMO Congress in Stockholm, 12-16 September 2008
Lugano (ots) - The 33rd ESMO Congress in Stockholm, the premier European congress in Oncology, serves as a meeting place for medical oncologists, as well as a focal point to exchange ideas with colleagues from other disciplines. The Congress Centre will be the venue for interdisciplinary interaction, a teaching ground, and a place to discuss critical issues for European oncology such as cancer research in Europe, the ...
plus
24.07.2008 – 14:57
Solianis Monitoring AG
Solianis' novel multisensor technology monitors hydration changes in skin - two patents submitted opening new horizons for cosmetic manufacturers and customers
Zurich (ots) - Solianis' new patents cover the basic technology to monitor changes in the hydration of skin at different depths and to evaluate the impact of cosmetic products: "Device and method for determining at least one characterizing parameter of multilayer body tissue" and "Method and device for ...
plus
22.07.2008 – 12:30
Helsinn Healthcare SA
Successful Inspection of Helsinn Birex Pharmaceuticals Dublin, Ireland by the US Food and Drug Administration
Dublin, Ireland (ots) - Helsinn is pleased to announce that Helsinn Birex Pharmaceuticals, its drug facility in Dublin Ireland, has undergone a successful inspection by the US Food and Drug Administration (FDA) without any Form 483 observations. The FDA visit, which lasted 5 days, was a pre-approval inspection ...
plus
09.07.2008 – 11:40
Helsinn Healthcare SA
Helsinn Healthcare SA announces the launch of ALOXI® (palonosetron hcl) injection for the prevention of postoperative nausea and vomiting in the USA
Lugano (ots) - Helsinn's Top Management and its U.S. partner Eisai Inc. today announced the availability in the USA of ALOXI® (palonosetron hydrochloride) injection 0.075 mg for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. The introduction of ALOXI® for PONV ...
plus
09.06.2008 – 10:00
Solianis Monitoring AG
Solianis' Non-Invasive Glucose Monitor Tracks Blood Glucose in Outpatient Study
Zurich (ots) - Solianis is conducting a study in which patients with diabetes are testing a preliminary functional model of the future device for non-invasive glucose monitoring. First results confirm the expected applicability of the multisensor platform in everyday life. Solianis' unique multisensor platform offers an easy and reliable monitoring of changes ...
plus
03.06.2008 – 10:30
DSM Nutritional Products AG
Good news for the summer: Beta-Carotene helps to protect against sunburn
Kaiseraugst (ots) - If "an apple a day keeps the doctor away", a carrot a day might help to keep the sun burn away. That is the conclusion of a recently published analysis by Professors Wolfgang Köpcke and Jean Krutmann, of Münster University Hospital and the Institut für Umweltmedizinische Forschung in Düsseldorf, Germany, respectively. In a paper ...
plus
27.05.2008 – 13:30
DSM Nutritional Products AG
Oily fish are good for you, but there is an alternative route to Omega-3
Basel (ots) - Herring sandwich? Mackerel soufflé? Salmon fondue? If these items don't form part of your diet, you might be missing out on something. That something is long-chain Omega-3 polyunsaturated fatty acids, a substance vital to good health which is found primarily in oily fish. Consumed regularly, Omega-3 can help in the battle against a variety of ...
plus
15.05.2008 – 10:15
Ergonex Pharma GmbH
Ergonex Pharma: Terguride receives FDA orphan drug designation for the treatment of pulmonary arterial hypertension
Appenzell (ots) - Ergonex Pharma today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to Terguride for the treatment of pulmonary arterial hypertension (PAH). Terguride is currently being evaluated for PAH in a pivotal Phase II trial in Europe. "The ...
plus
03.03.2008 – 18:00
Helsinn Healthcare SA
FDA approves ALOXI® (Palonosetron HCl) injection for prevention of postoperative nausea and vomiting
Lugano (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, together with its partner EISAI Corporation of North America and EISAI's U.S. subsidiary, MGI Pharma, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi® (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for ...
plus
27.02.2008 – 09:00
Solianis Monitoring AG
Continuous non-invasive glucose monitoring - Solianis Monitoring AG: Multi-sensor technology drives clinical progress
Zürich (ots) - Solianis sees its Multi-Sensor Technology as a promising approach to continuous non-invasive glucose monitoring. Professor Marc Donath, member of the Solianis Scientific Advisory Board and Professor for endocrinology and diabetology at the University Hospital in Zürich, Switzerland, has ...
plus
12.02.2008 – 11:37
Juvena of Switzerland
Juvena of Switzerland: Live Chat with Prof. Dr. Sven Gohla. Topic: Skincare
Volketswil-Zurich (ots) - Juvena of Switzerland, a Swiss cosmetics company established in 1954, launched its Juvedical renewing serum in 2004, thus attracting an ever-growing fan base. Consumers love the product, and express their enthusiasm in letters and emails, which the company receives daily. Physicians and scientists-as well as 15 international awards-confirm ...
plus
11.02.2008 – 11:08
Helsinn Healthcare SA
Helsinn Healthcare SA announces the launch of Aloxi® (Palonosetron) in the UK
Lugano, Switzerland (ots) - Helsinn Healthcare SA, a Swiss pharmaceutical group, is pleased to announce, ahead of schedule, today's launch in the UK of Aloxi® (Palonosetron hydrochloride), a new generation treatment for chemotherapy induced nausea and vomiting, by its local partner Maelor plc, the specialist hospital medicines group. Aloxi® is a patented ...
plus
05.02.2008 – 22:58
Eli Lilly and Company
Global 'Inspired by Diabetes' Creative Expression Competition Deadline Extended Until March 31, 2008
Indianapolis (ots/PRNewswire) - - Global contest seeks expressions of the triumphs and challenges of living with diabetes through art, essay, poetry, photography and music Eli Lilly and Company, the International Diabetes Federation (IDF), and the International Society for Pediatric and ...
plus
04.02.2008 – 17:36
Acrongenomics Inc.
Acrongenomics Acquires Equity Stake in Molecular Vision
Geneva (ots/PRNewswire) - Acrongenomics, Inc. (OTC: AGNM) is pleased to announce that they have acquired a 10.9% interest in Molecular Vision Limited, on a fully diluted basis. The cash consideration will be used by Molecular Vision for working capital and to further develop its technology. Molecular Vision is developing low cost easy-to-use credit-card sized devices for medical testing that will greatly extend ...
plus
04.02.2008 – 10:37
Janssen-Cilag AG
Promising Phase 3 Data for Ustekinumab (CNTO 1275) in Long-Term Improvement of Chronic Plaque Psoriasis
San Antonio, Texas (ots/PRNewswire) - - New Findings From a Second Pivotal Phase 3 Study Show Subjects Receiving Ustekinumab Every 12 weeks Maintained Improvement From Psoriasis Through One Year One-year data from the second double blind, placebo-controlled Phase 3 study PHOENIX 1 showed therapy with ...
plus
04.02.2008 – 07:35
Roche Pharmaceuticals
EU Grants Broad Approval of Xeloda for Patients With Metastatic Colorectal Cancer
Basel, Switzerland (ots/PRNewswire) - - Many More Patients Can Now Benefit From Oral Chemotherapy That Significantly Reduces Treatment Time Roche announced today that the European Commission has approved its oral chemotherapy Xeloda (capecitabine) for the treatment of metastatic colorectal cancer in combination with any chemotherapy in all lines of ...
plus
01.02.2008 – 15:37
Abbott Laboratories
Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France
Abbott Park, Illinois (ots/PRNewswire) - - Improved Medical Benefit Rating Granted for XIENCE V from French Health Authority Abbott (NYSE: ABT) today announced that it has received reimbursement approval in France for its XIENCE(TM) V Everolimus Eluting Coronary Stent System, the first drug eluting stent to demonstrate clinical superiority over another drug ...
plus
28.01.2008 – 18:14
Wyeth Pharmaceuticals
EMEA Validates Wyeth Application to Expand the European Label of TORISEL
Maidenhead, England (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced today that the European Medicines Agency (EMEA) has validated the marketing authorisation application for Torisel(R) (temsirolimus) for treating relapsed and/or refractory mantle cell lymphoma (MCL), a rare type of non-Hodgkin's lymphoma (NHL) that accounts for ...
plus
28.01.2008 – 12:10
Abbott Laboratories
Abbott's Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
Abbott Park, Illinois (ots/PRNewswire) - - Lopinavir/ritonavir tablet is the first and only co-formulated protease inhibitor tablet approved for use in children with HIV Abbott (NYSE: ABT) announced today that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee ...
plus
28.01.2008 – 08:10
sanofi-aventis Group
Clexane(R)/Lovenox(R) Approved in Japan
Paris (ots/PRNewswire) - Sanofi-aventis announced today that the anticoagulant Clexane(R) (enoxaparin sodium injection) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the prevention of venous thromboembolism (VTE) in patients undergoing orthopaedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery. Venous ...
plus
28.01.2008 – 07:35
Roche Pharmaceuticals
Many More Patients Can Now Benefit From Avastin's Proven Survival Benefits
Basel, Switzerland (ots/PRNewswire) - - Avastin Receives Broad Label Extension in Europe for the Treatment of Patients With Metastatic Colorectal Cancer Roche announced today that the European Commission (EC) has given its approval for the significantly wider use of its anti-angiogenic agent Avastin (bevacizumab) in patients suffering from ...
plus
24.01.2008 – 09:03
European Influenza Surveillance Scheme (EISS)
Europe's Winter Flu Season Starts
Utrecht, The Netherlands and Stockholm, Sweden (ots/PRNewswire) - The 'flu' has arrived in Europe, according to the European Influenza Surveillance Scheme (EISS) and the European Centre for Disease Prevention and Control (ECDC). The two organisations confirm an upsurge in the number of laboratory confirmed cases of influenza in several European countries. As of this week, 13 European countries are reporting significant influenza activity (Austria, Bulgaria, France, ...
plus
18.01.2008 – 12:08
Vasogen Inc.
The Lancet Publishes Vasogen's ACCLAIM Results
Mississauga, Canada (ots/PRNewswire) - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that The Lancet, a world-leading medical journal, will publish an article entitled 'Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial' in its January 19th issue (Lancet 2008; 371: 228-36). The article describes the results from Vasogen's ...
plus
18.01.2008 – 08:33
Novagali Pharma
Novagali Pharma Announces FDA Clearance of IND for US Clinical Trial of Nova63035 in Patients With Diabetic Macular Edema
Evry, France (ots/PRNewswire) - - Not for Distribution in the United States, Canada or Japan Novagali Pharma, an emerging ophthalmic pharmaceutical company announced today that the Company's Investigational New Drug Application (IND) to conduct a Phase I clinical trial of its Nova63035, an ophthalmic ...
plus
16.01.2008 – 17:59
CEVA Logistics
CEVA Logistics Appoints Peter Dew as Group Chief Information Officer
Hoofddorp, The Netherlands (ots/PRNewswire) - CEVA Logistics, the 4th largest supply chain company worldwide, has appointed Peter Dew as Group Chief Information Officer (CIO), effective April 1, 2008. He will be responsible for establishing and implementing CEVA's IT strategy at a global level. Peter Dew has a wealth of experience from similar roles in major international corporations. Prior to joining CEVA, he was ...
plus
15.01.2008 – 14:06
AstraZeneca GmbH
First Head to Head Study Comparing Crestor(TM) and Lipitor(R) Effects on the Treatment of Atherosclerosis
London (ots/PRNewswire) - AstraZeneca (LSE: AZN) (NYSE: AZN) today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare ...
plus
14.01.2008 – 20:37
Roche Pharmaceuticals
Roche Responds to Announcement of "IDEAL" Hepatitis C Study
Basel, Switzerland (ots/PRNewswire) - Following an announcement from Schering-Plough, Roche today affirmed the value of PEGASYS(R) (peginterferon alfa-2a) in combination with COPEGUS(R) (Roche's brand of ribavirin) as the market-leading treatment for patients with hepatitis C. Despite clear biases in the design of the "IDEAL" study that potentially favoured patients taking PegIntron(TM) (peginterferon alfa-2b) regimens ...
plus
14.01.2008 – 17:15
Resverlogix Corp.
Progress Report from RVX-208 Phase 1 Clinical Study
Calgary, Canada (ots/PRNewswire) - - Resverlogix Sees Early Success and Expedites Phase 2 Plans TSX Exchange Symbol: RVX Resverlogix is pleased to announce preliminary data from the RVX-208 Phase 1 safety and pharmacokinetics study. Forty healthy volunteers have so far been treated of which sixteen have received multiple doses. As anticipated from the extensive Investigational New Drug toxicology studies no ...
plus
11.01.2008 – 23:02
CBMI Canada
cbm Responds to the Humanitarian Crisis in Kenya
Nairobi (ots/PRNewswire) - cbm through its staff and Regional Office in Nairobi is providing emergency assistance to the humanitarian crisis in Kenya. It is estimated that around 500,000 people have lost their homes, due to the widespread violence following the disputed election. Prof. Allen Foster, cbm's President announced, "There is an urgent need of food, shelter and health services, and cbm will ...
plus
07.01.2008 – 14:34
Roche Pharmaceuticals
Benefits of Oral Xeloda Over Continuous Intravenous Chemotherapy Confirmed for Advanced Stomach Cancer
Basel, Switzerland (ots/PRNewswire) - - For non US or non UK Media Only - Oral Chemotherapy Tablet Option Reduces the Time Patients Need to Spend in the Hospital Data recently published in the New England Journal of Medicine confirm oral chemotherapy tablet Xeloda (capecitabine) as a first-line ...
plus

Précédent61626364656667686970Suivant